|
Robert R. Ruffolo (born April, 1950, in Yonkers, N.Y.) was president of research and development for Wyeth Pharmaceuticals, and corporate Senior Vice President of Wyeth from 2001 to 2008. During his career in the pharmaceutical industry, Ruffolo played a significant role in the discovery and/or development of a number of marketed products, including dobutamine (Dobutrex) for the acute management of congestive heart failure, and eprosartan (Teveten) for hypertension. == Biography == Robert R. Ruffolo, Jr. was born in April 1950, in Yonkers, N.Y. He had Bachelor of Science in pharmacy, 1973, Ohio State University; PhD in pharmacology, 1976, also in Ohio. Spent a few years as a fellow at the National Institutes of Health, then spent 6 years at Eli Lilly & Co. and 17 years at SmithKline Beecham in various research positions. He joined Wyeth in 2000. Ruffolo has authored nearly 500 full-length publications and 200 abstracts, and has edited 17 books. He is currently the Editor-in-Chief of ''Current Opinions in Pharmacology''. Ruffolo has served on the editorial boards of 28 international scientific journals. The American Society for Information Science and Technology designated Ruffolo as a Highly Cited Scientist for being among the top one-hundred most cited pharmacologists in the world over the past two decades. Robert is married and has three children. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Robert R. Ruffolo, Jr」の詳細全文を読む スポンサード リンク
|